

Immunoglobulin Prescription Form Please fax completed order form to 502.515.3509

after blood draw

NO Heparin needed

Groshong PICC, Midline

5694 Shepherdsville Road | Louisville, KY 40228

OFFICE: 502.515.3500 F	AX: 502.515.3509	<u>Prescription:</u>					
·		☐ Intravenous Immunoglobulin ☐ Subcutaneous Immunoglob					ulin
<u>Demographic Information:</u>		□ 0.4 gm/kg □1gm/kg □2gm/kg □ grams					
Patient Name	Date of Birth	Infuse: ☐ IV daily x day(s); repeat every		cvcles	Infuse grams	OR mls	;
Patient Name	Date of Bil th	Dother:		,	using sites		
Home Address		Hydration order:mls NS iv to be infused prior/post IVIG. formonths.					
		□ Pre-medications: Acetaminophen 650mg PO 30			er Pre-medications:		
City, State, Zip		Diphenhydramine 25mg PO 30) mins prior to infusion	า			
		<u>Clinical Information:</u>					
Home Phone Mobile or Work Phone		Dakiash Walahk					
		Patient Weight: Height: Allergies:					
Primary Insurance Name		IV access [for IVIg patients only]:		□ Nurs	se to place PIV prior to the	erapy	
Primary Insurance Group		Diagnosis	ICD-10	Diagr	Diagnosis		ICD-10
		Neuromuscular:	102.10	- 3	nune Deficiency:		102 10
Insured Name Insured Date of Birth		☐ Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)) G61.81	□ CVID v	☐ CVID w/ Predominant Immunoregulatory T-Cell Disorders		D83.1
		☐ Dermatopolymyositis	M33.90	☐ Combi	ned Immunodeficiency, Unspecified		D81.9
		☐ Guillain-Barre Syndrome (GBS)	G61.0	□ Comm	☐ Common Variable Immunodeficiency, Unspecified		D83.9
Secondary Insurance Name	Insurance ID Insurance Group	☐ Multifocal Motor Neuropathy	G61.82		tary Hypogammaglobulinemia		D80.0
		☐ Myasthenia Gravis (MG)	G70.0		nodeficiency with Increased IgM		D80.5
Secondary Insurance ID Secondary Insurance Group		☐ Myasthenia Gravis with (Acute) Exacerbation G70.01			□ Nonfamilial Hypogammaglobulinemia		D80.1
•		☐ Polymyositis	M33.20		combined Immunodeficiencies		D81.89
Ondering Discriptor/s Name		☐ Relapsing Remitting Multiple Sclerosis (RRMS) G:		☐ Other Common Variable Immunodeficiencies		D83.9	
Ordering Physician's Name		☐ Stiff Person Syndrome	G25.82				L12.0
		Other:		□ Pemph			L10.9 D81.2
Address		☐ Autoimmune Encephalopathy	G04.81	□ SCID with Low or Normal B-Cell Numbers			D81.2
		☐ Idiopathic Thrombocytopenic Purpura ☐ Inflammatory Neuropathies	D69.3	☐ SCID with Low T- and B- Cell Numbers ☐ Selective deficiency of IqG Subclasses			D81.1
City, State, Zip		- Initialificatory Neuropatriles	G61.89		c Antibody Deficiency		D80.6
orty, State, Zip					nic lupus erythematosus (SLE)		M32.9
		L		Боумен	ne rapus erytriematosus (SEE)		
Phone	Fax	Please Draw: PER Anaphylaxis Protocol:					
		□ CBC/diff □ CMP □ IaG w/subclasses 1-	4 - Ouant Ia		piPen 0.3 auto-injector dual pack		
NPI		3	-4 🗆 Quant. 19		☐ Pediatric – EpiPen 0.15 auto-injector dual pack * Administer intramuscularly in the event of ADR*		
Please fax the following	information:	□ □ Frequency:		[May repeat	x 1. Order is valid for 1 year]. **Use	generic if applicab	e**
□ History and Physical □ Pertinent Lab Work		Notes:	If applicable, flush intravenous access device per KabaFusion protocol				n protocol:
□ Front & Back copy(s) of patient's insurance card(s)			Access		NS	Heparin	
			Peripheral		1-3ml before/after use	10u/ml 1-2mls after last NS flush	
I authorize KabaFusion and its representatives to act as an agent and initiate and execute any insurance prior authorization process for this prescription, and any future					NS 5-10 mls before/after use; 10mls after blood draw	10 u/ml 3-5mls after last NS flush; 5mls after blood draw	
fills of the same prescription for the patient listed above. I understand that I can					5-10mls before/after use; 20mls after blood draw	ls 100 u/ml 5mls after last NS flush; 5mls after blood draw	
revoke this designation at any time by providing written notice to KabaFusion.			Tunneled 5		5-10mls before/after use; 20mls after blood draw	10 u/ml 3- mls after last NS flush. 5mls after blood draw	
Physician Signature:			Croshong BICC Midling		5-10mls before/after use; 10mls		

CONFIDENTIALITY NOTICE: The following includes confidential, proprietary information that is the sole exclusive property of KabaFusion, LLC. No rights in, relating to, or derived from such information are assigned or otherwise transferred by this document, and the recipient of such information is subject to obligations of secrecy to and for the benefit of KabaFusion, LLC. Any unauthorized use or disclosure of such information is strictly prohibited. This message, together with any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination, or copying of this message, or any attachment, is strictly prohibited. If you have received this message in error, please notify the original sender immediately by telephone or by return fax and shred this document along with any other documents. Thank you.